Drug Profile
Research programme: MAPKAP K2 inhibitors - Astex Therapeutics
Alternative Names: MAPKAP K2 inhibitors research programme - Astex TherapeuticsLatest Information Update: 31 May 2006
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Class
- Mechanism of Action Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 31 May 2006 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
- 31 May 2006 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 09 Aug 2005 Astex Technology Ltd is now called Astex Therapeutics